However, fourth place is held by a dark horse: cassava. While nearly unknown in temperate climates, cassava is a key source ...

In our series of letters from African journalists, Ghanaian Elizabeth Ohene considers the call of Uganda's President Yoweri Museveni for people to eat the humble cassava as the price of wheat ...

Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC. The SEC said that Cassava made misleading statements about a clinical trial of its ...

Cassava Sciences' stock rose 9% after completing an interim safety analysis for its Alzheimer's drug, Simufilam, but the company's future remains uncertain due to ongoing legal and scientific ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made misleading statements about phase 2b data on its Alzheimer’s disease drug candidate. The U.S ...

Fintel reports that on October 8, 2024, HC Wainwright & Co. upgraded their outlook for Cassava Sciences (NasdaqCM:SAVA) from ...

The research behind Cassava Sciences’ Alzheimer’s drug candidate, simufilam, and the idea of targeting a brain protein called filamin, is based on a series of papers from a group at CUNY and ...

Alzheimer’s drug developer Cassava Sciences agreed Thursday to pay $40 million to settle regulatory claims that it misled investors about the results of a clinical trial that showed promise for ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Cassava Sciences faced a $40 million penalty to focus on Simufilam's development following SEC charges over misleading trial data. Cassava Sciences completed ReTHINK Phase 3 trial with 804 ...

Cassava, without admitting or denying the SEC’s allegations, agreed to pay a monetary penalty of $40 million. The Company cooperated fully with the SEC’s investigation and has implemented ...

AUSTIN, Texas, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the completion of a third interim ...